BERRY GENOMICS(000710)

Search documents
贝瑞基因(000710) - 2015 Q4 - 年度财报
2016-04-05 16:00
Financial Performance - The company's operating revenue for 2015 was ¥230,056,809.46, a decrease of 15.93% compared to ¥273,643,289.35 in 2014[16] - The net profit attributable to shareholders was -¥13,008,739.61, representing a decline of 289.13% from a profit of ¥6,878,248.23 in the previous year[16] - The net cash flow from operating activities was -¥70,809,801.88, a significant drop of 474.46% compared to ¥18,909,920.32 in 2014[16] - The basic earnings per share for 2015 was -¥0.0860, down 289.01% from ¥0.0455 in 2014[16] - The weighted average return on net assets was -10.53%, a decline of 16.32% compared to 5.79% in the previous year[16] - The company reported a total operating revenue of CNY 230.06 million in 2015, a decrease of 15.93% compared to CNY 273.64 million in 2014[30] - The net profit attributable to the parent company was CNY -13.01 million, down 289.13% from the previous year[30] - The company faced significant challenges due to macroeconomic pressures and a downturn in the domestic automotive market, impacting its revenue and profit targets[30] - The company reported a significant increase in financing cash flow, up 205.30% to ¥31,888,866.46, mainly due to increased bank loans[50] - The company reported a net loss in retained earnings of CNY -93,352,835.94 compared to CNY -80,344,096.33, indicating a worsening of approximately 16.5%[171] Assets and Liabilities - The total assets at the end of 2015 amounted to ¥498,882,491.13, an increase of 11.89% from ¥445,853,810.22 at the end of 2014[16] - The total assets at the end of 2015 were ¥498,000,000, with cash and cash equivalents decreasing by 9.35% to ¥67,038,723.66[54] - The total equity attributable to shareholders decreased to CNY 117,688,545.41 from CNY 130,028,467.60, a decline of approximately 9.4%[171] - Current assets decreased to CNY 215,781,959.56 from CNY 265,130,674.15, a decline of about 18.7%[169] - Long-term investments increased to CNY 113,058,766.63 from CNY 89,639,904.02, reflecting a growth of about 26.1%[170] - Non-current liabilities increased significantly to CNY 125,827,508.80 from CNY 23,131,041.00, an increase of about 444%[171] Revenue Sources and Market Performance - The company experienced a significant increase in non-operating income, with a total of ¥426.71 in 2015 compared to ¥26,634,280.73 in 2014[22] - The sales of automotive parts accounted for 97.65% of total revenue, with a year-on-year increase of 11.17%[33] - The Southwest region's revenue dropped by 44.73% to CNY 84.50 million, while the Central region saw a 134.94% increase to CNY 35.24 million[34] - The company aims to achieve a certain percentage increase in revenue, total profit, and net profit in 2016[66] - The company is committed to expanding its market presence in mid-to-high-end and new energy vehicle segments[66] Research and Development - The company has enhanced its R&D capabilities, particularly in software development, and has begun to shift its product focus towards higher-value segments such as SUVs and electric vehicles[28] - Research and development investment amounted to ¥13,080,000, which is 5.69% of the operating revenue and 11.11% of the net assets[47] - The number of R&D personnel increased by 11.67% to 67, making up 10.09% of the total workforce[48] - The company recognizes the risks posed by market competition and will enhance its R&D efforts to mitigate these risks[67] Corporate Governance and Compliance - The company has committed to ensuring financial independence, including establishing an independent financial department and maintaining separate bank accounts from its controlling shareholder[79] - The company has committed to minimizing related party transactions and ensuring fair pricing in unavoidable transactions[79] - The company guarantees the independence of its personnel and assets post-transaction, with key management roles filled through legal procedures[78] - The company has maintained compliance with its commitments since 2012, with ongoing normal performance[76] - The independent directors did not raise any objections to company matters during the reporting period[150] Employee and Management Structure - The total remuneration for directors, supervisors, and senior management from the company during the reporting period amounted to CNY 1.146 million[137] - The company has 14 current directors, supervisors, and senior management as of December 31, 2015, with 10 receiving remuneration from the company[139] - The company implements a performance-based salary system, distributing wages based on employee contributions, abilities, and responsibilities[140] - The company emphasizes employee training, with plans for new employee onboarding, operational skills training for production staff, and professional training for management and technical personnel[141] Future Plans and Investments - The company plans to improve its production environment and management capabilities to remain competitive in the market[26] - The company plans to enhance its production capacity and quality assurance capabilities through technological upgrades during its relocation[66] - The company has made substantial investments in hardware, amounting to over CNY 5 million, to improve production capacity and efficiency[28] - The company is actively working on the construction of a new factory, with a land area of 60,675.53 square meters, which has already commenced[80] Financial Reporting and Audit - The financial report for the year ended December 31, 2015, was prepared in accordance with accounting standards and fairly reflected the company's financial position and operating results[162] - The audit opinion on the internal control effectiveness was standard and unqualified, confirming the effectiveness of financial reporting internal controls as of December 31, 2015[159] - The company reported no significant internal control deficiencies during the reporting period[156] - The internal control self-assessment report indicated that 100% of the total assets and operating income of the evaluated units were included in the consolidated financial statements[156]
贝瑞基因(000710) - 2015 Q3 - 季度财报
2015-10-27 16:00
Financial Performance - Total assets at the end of the reporting period were CNY 440,124,318.36, a decrease of 1.29% compared to the end of the previous year[7]. - Operating revenue for the reporting period was CNY 41,051,087.78, down 24.70% year-on-year, and CNY 151,182,040.82, down 28.54% year-to-date[7]. - Net profit attributable to shareholders was a loss of CNY 2,847,217.24, a decrease of 12.80% year-on-year, and a loss of CNY 7,681,753.31 year-to-date, down 7.75%[7]. - The net cash flow from operating activities was CNY -72,055,519.71, a decrease of 460.09% year-to-date[7]. - Basic and diluted earnings per share were both CNY -0.0188, down 12.57% year-on-year[7]. - The weighted average return on net assets was -2.90%, a decrease of 0.70% year-on-year[7]. - Cash and cash equivalents decreased by 43.66% compared to the beginning of the year, mainly due to payments for new factory construction[14]. - Prepaid accounts increased by 213.45% compared to the beginning of the year, primarily due to increased prepayments for new factory construction[14]. - Other income increased by 386.01% year-on-year, mainly due to government technology project funding[14]. Corporate Governance and Compliance - The company has committed to avoiding competition with Tianxing Instrument, ensuring no investment in similar businesses as of March 14, 2012[15]. - The company and its controlling subsidiaries will minimize related party transactions with Tianxing Instrument, ensuring fair pricing based on independent third-party standards[17]. - The company guarantees the independence of Tianxing Instrument's personnel, assets, business, and finances post-transaction completion[17]. - The company has committed to ensuring independent financial operations and governance structures, reinforcing its operational autonomy[18]. - The management team is dedicated to maintaining compliance with legal and regulatory requirements in all transactions and restructuring efforts[19]. - The company reported no violations regarding external guarantees during the reporting period[27]. - There were no non-operating fund occupations by controlling shareholders or their affiliates during the reporting period[28]. Strategic Planning and Restructuring - The company reported a significant operational challenge, indicating that it could not independently overcome its business difficulties and required external assistance for restructuring[18]. - The planned major asset restructuring was suspended due to the inability to meet the prerequisites outlined in the asset purchase agreement, with a commitment to resume efforts post completion of state-owned share transfer[19]. - The company has committed to resolving the separation of property rights concerning its buildings and land, ensuring clear ownership relationships within 12 months following the completion of the acquisition[19]. - The new factory construction is actively progressing, with the company having signed a land use rights transfer contract for 60,675.53 square meters of state-owned land[19]. - The company engaged in multiple strategic discussions regarding major asset restructuring with various institutional investors throughout the reporting period[25]. - The company did not provide any materials during the discussions about its strategic direction and major asset restructuring[25]. - The company conducted several in-person research and communication activities with institutional investors to discuss its strategic plans[26]. - The company’s board of directors was involved in communications with individual investors regarding major asset restructuring and operational conditions[26]. - The company’s chairman is Wen Wu, who oversees the strategic direction of the company[29]. Future Outlook - The forecast for the cumulative net profit for the year is uncertain, with potential for significant fluctuations compared to the previous year[21]. - The company has not provided any specific user data or future performance guidance in the available reports[26].
贝瑞基因(000710) - 2015 Q2 - 季度财报
2015-08-25 16:00
Financial Performance - The company's operating revenue for the first half of 2015 was CNY 110,130,953.04, a decrease of 29.88% compared to the same period last year[20]. - The net profit attributable to shareholders was a loss of CNY 4,834,536.07, representing a decrease of 4.98% year-on-year[20]. - The net cash flow from operating activities was a negative CNY 40,965,230.40, which is a decline of 104.14% compared to the previous year[20]. - The overall profitability of the company remains low, resulting in continued losses during the reporting period[29]. - The company reported a basic earnings per share of -CNY 0.0320, a decrease of 4.92% from the previous year[20]. - The company reported a net loss of CNY 85,178,632.40, worsening from a loss of CNY 80,344,096.33 in the previous period[107]. - The total comprehensive income for the first half of 2015 was -4,834,536.07 CNY, slightly worse than -4,674,365.54 CNY in the previous year[111]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 472,205,561.92, an increase of 5.91% from the end of the previous year[20]. - The net assets attributable to shareholders decreased by 3.72% to CNY 125,193,931.53 compared to the end of the previous year[20]. - Total liabilities increased to CNY 347,011,630.39 from CNY 315,825,342.62, which is an increase of approximately 10%[106]. - Non-current liabilities rose significantly to CNY 79,461,000.00 from CNY 23,131,041.00, reflecting a substantial increase of over 243%[106]. Cash Flow - The net cash flow from investing activities was -¥5,684,154.52, a significant decrease of 573.40% year-over-year[31]. - The net cash flow from financing activities increased by 37.94% to ¥23,811,746.67 due to increased bank borrowings[31]. - The company's cash and cash equivalents decreased by ¥22,807,156.01, a decline of 1,349.95% compared to the previous year[31]. - The company's cash and cash equivalents at the end of the period amounted to ¥82,271,705.38, down from ¥101,598,861.39 at the beginning of the period, representing a decrease of approximately 19%[194]. Operational Challenges - The company faced challenges due to a slowdown in the domestic macroeconomic growth and intense competition in the mid-to-low-end automotive industry[29]. - The company reported that it is facing significant operational difficulties and needs external assistance to adjust its business structure[79]. Investment and Development - The company is focusing on enhancing technology research and development, accelerating product transformation, and actively promoting cost reduction efforts[29]. - The company invested ¥96,315,440.41 during the reporting period, a 55.57% increase compared to the same period last year[37]. - The company has signed a land use rights transfer contract for 60,675.53 square meters of state-owned construction land, with construction of a new plant already underway[80]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,897[90]. - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., holds 58.86% of the shares, totaling 89,002,000 shares[92]. - The company plans to not distribute cash dividends or issue bonus shares for this period[6]. Related Transactions - The company reported a total of 4,118.8 million yuan in related transactions during the reporting period[64]. - The company confirmed that all related transactions were within the expected range set at the beginning of the reporting period[64]. - The company engaged in related transactions with Chengdu Tongyu Automotive Parts Co., Ltd., with sales amounting to 2.46 million yuan, accounting for 0.02% of the total[63]. Accounting Policies - The financial statements are prepared based on the company's ability to continue as a going concern for at least 12 months from the reporting date[125]. - The company adheres to the accounting policies and estimates as per the enterprise accounting standards, ensuring the financial statements reflect true and complete information[127]. - The company has not made any significant changes to its accounting policies during the reporting period, maintaining consistency in financial reporting[189]. Employee Benefits - The company recognizes employee compensation as liabilities during the accounting period when services are provided, including short-term and long-term benefits[176]. - The company’s short-term employee benefits are expected to be fully paid within twelve months, aligning with the accounting treatment for such liabilities[180].
贝瑞基因(000710) - 2015 Q1 - 季度财报
2015-04-24 16:00
Financial Performance - Revenue for Q1 2015 was CNY 46,550,895.79, a decrease of 13.59% compared to CNY 53,871,913.31 in the same period last year[8] - Net profit attributable to shareholders was a loss of CNY 5,524,773.70, representing a decline of 279.54% from a loss of CNY 1,455,664.14 in the previous year[8] - Basic earnings per share decreased by 280.21% to CNY -0.0365 from CNY -0.0096 year-on-year[8] - Net cash flow from operating activities was CNY -38,272,637.01, a decline of 53.78% compared to CNY -24,887,859.65 in the previous year[8] - Total assets at the end of the reporting period were CNY 450,862,797.92, an increase of 1.12% from CNY 445,853,810.22 at the end of the previous year[8] - Net assets attributable to shareholders decreased by 4.25% to CNY 124,503,693.90 from CNY 130,028,467.60 at the end of the previous year[8] Business Operations - The main business of Tianxing Instrument includes design, production, processing, and sales of motorcycle and automotive parts[19] - The company has signed a contract to acquire 60,675.53 square meters of state-owned construction land use rights, with construction of a new factory already underway[22] - The company aims to enhance its core competitiveness through external adjustments to its existing business structure[21] Related Party Transactions - The company commits to minimizing related party transactions with Tianxing Instrument and will sign standardized agreements for unavoidable transactions[19] - The pricing of related party transactions will be determined based on prices from independent third parties for similar transactions to ensure fairness[19] - The company guarantees to fulfill information disclosure obligations regarding related party transactions as per relevant laws and regulations[19] - The company has pledged to minimize related party transactions and ensure fair pricing in any unavoidable transactions[21] Corporate Governance - The company is committed to ensuring the independence of its operations, including personnel, assets, and financial management, to avoid conflicts of interest with its controlling shareholder[20] - The company guarantees that its financial department operates independently and that it maintains a separate bank account from its controlling shareholder[20] - The company is focused on maintaining a complete and independent organizational structure to support its business activities[20] - The company has made commitments regarding the independence of its management personnel, ensuring that key executives are solely employed by the listed company[20] Strategic Initiatives - The company is actively pursuing a major asset restructuring, which has been temporarily halted due to the inability to meet certain conditions outlined in the asset purchase agreement[21] - The company is working on clarifying property rights related to its factory and office buildings, ensuring that the interests of the listed company are not compromised[21] - The company has committed to creating conditions for advancing its restructuring efforts after the completion of state-owned share transfers[21] Investor Relations - The company received feedback from the China Securities Regulatory Commission regarding its administrative licensing project on March 20, 2015, and is preparing relevant materials[16] - The company engaged in discussions regarding its strategy and major asset restructuring with various institutional investors on March 10 and March 26, 2015[27] - No materials were provided during the discussions on company strategy and major asset restructuring[27] - The company communicated with individual investors regarding major asset restructuring from January 1 to March 31, 2015[27] Miscellaneous - As of the date of the commitment letter, the company has not invested in any companies with similar business to Tianxing Instrument[19] - The company and its controlled entities will not engage in any business activities that may compete with Tianxing Instrument and its subsidiaries[19] - The commitment to avoid competition will be maintained during the period of indirect control over Tianxing Instrument[19] - The company will notify Tianxing Instrument of any substantial business opportunities that may compete with its main business[19] - The commitment to avoid competition is a long-term obligation and is currently being fulfilled normally[19] - The company ensures that no activities will harm the interests of Tianxing Instrument[19] - There were no securities investments during the reporting period[24] - The company did not hold shares in other listed companies during the reporting period[25] - There were no derivative investments during the reporting period[26] - The chairman of the company is Wen Wu[28]
贝瑞基因(000710) - 2014 Q4 - 年度财报
2015-03-24 16:00
Financial Performance - The company's operating revenue for 2014 was ¥273,643,289.35, an increase of 4.35% compared to ¥262,234,824.69 in 2013[22]. - The net profit attributable to shareholders in 2014 was ¥6,878,248.23, a significant turnaround from a loss of ¥6,156,854.77 in 2013, representing a 211.72% increase[22]. - The net cash flow from operating activities was ¥18,909,920.32, up by 21.00% from ¥15,627,955.37 in the previous year[22]. - The total assets at the end of 2014 amounted to ¥445,853,810.22, reflecting an 8.72% increase from ¥410,084,460.18 at the end of 2013[22]. - The net assets attributable to shareholders increased by 12.64% to ¥130,028,467.60 from ¥115,439,083.27 in 2013[22]. - The basic earnings per share for 2014 was ¥0.0455, compared to a loss of ¥0.0407 per share in 2013, marking a 211.79% improvement[22]. - The weighted average return on equity was 5.79%, a recovery from -5.36% in the previous year, indicating a positive trend in profitability[22]. - The company reported a gross profit margin of 13.45% for its main business, with operating costs amounting to CNY 255.37 million[36]. - The company reported a significant increase in investment income of CNY 41,783,111.42, compared to CNY 9,334,283.25 in the previous year[184]. Business Operations - The company has reported no significant changes in its main business since its listing[19]. - The company has detailed risk factors and countermeasures in its report regarding future development challenges[13]. - The main business revenue was CNY 236.78 million, which constituted 86.53% of total operating revenue[31]. - The company’s sales volume decreased by 13% to 117,000 units, while production volume also fell by 11% to 119,000 units[32]. - The top five customers accounted for 52.24% of total sales, with Chongqing Changan Automobile Co., Ltd. being the largest customer at 20.56%[33]. - The company’s non-current asset disposal profit was CNY 26.25 million, a significant recovery from a loss in the previous year[28]. - The company developed 92 new products during the reporting period, with 53 products entering mass production[52]. - The company invested over $3 million in technological upgrades, enhancing production efficiency and product quality[52]. Financial Management - The company’s financial expenses increased by 39.09% to CNY 7.75 million, primarily due to increased discount interest on notes[39]. - The company aims to broaden its financing channels and improve cash flow management to mitigate financial risks associated with macroeconomic policy adjustments[71]. - The company reported a stable financial condition with normal cash flow, indicating a healthy operational status[121]. - The company has a total of 151,200,000 shares, all of which are unrestricted[115]. - The company has engaged in repurchase agreements, with Guangfa Securities holding 660,000 shares, representing 0.44% of the total shares[120]. Strategic Plans - The company aims to achieve a certain percentage increase in revenue, total profit, and net profit in 2015, focusing on upgrading its automotive instrument sector and expanding the market for liquid crystal instruments[67]. - The company plans to stabilize and develop its outsourcing market, aiming to cultivate it as a new economic growth point in 2015[68]. - The company will enhance cost reduction and efficiency improvement measures, including procurement cost reduction and process innovation, to increase profitability[69]. - The company is actively pursuing technology breakthroughs and independent innovation to enhance its competitive edge in the electronic instrument market[70]. - The company is committed to enhancing its core competitiveness and sustainable development capabilities through internal management improvements and strategic restructuring[67]. Related Party Transactions - The total amount of related party transactions for the year was CNY 10,993.42 million, with various transactions including sales and purchases of materials[91]. - The company sold products and materials to related parties at market prices, with sales amounting to CNY 524.94 million, representing 1.92% of total sales[91]. - The company purchased raw materials from related parties for CNY 3,316.57 million, accounting for 14.65% of total purchases[91]. - The company engaged in related party transactions to leverage existing sales channels and reduce operational costs, ensuring continued business operations[91]. - The company confirmed that its main business operations would not become dependent on related parties as a result of these transactions[91]. Governance and Compliance - The company’s governance structure complies with the requirements of the Company Law and the relevant regulations of the China Securities Regulatory Commission[146]. - The company has established a series of training programs for employees, including onboarding training for new hires and professional training for management and technical staff[143]. - The company has a comprehensive internal control system to ensure legal compliance and asset security[162]. - The independent directors' suggestions were actively listened to and adopted by the company[154]. - The company operates independently from its controlling shareholder in business, personnel, and financial aspects[160]. Human Resources - As of December 31, 2014, the company had 714 employees, including 488 production personnel, 105 technical personnel, and 25 sales personnel[141]. - The company implemented a performance-based salary system for employees, focusing on contributions, abilities, and responsibilities[143]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 1.1343 million, with independent directors receiving a total of CNY 150,000[135]. - The company has not experienced any changes in its core technical team or key technical personnel that would significantly impact its core competitiveness during the reporting period[140]. Asset Management - The company signed a land use rights transfer agreement for 60,675.53 square meters, and the new factory construction is currently underway[108]. - The company has committed to resolving the separation of property and land rights, ensuring clear ownership and compliance with legal requirements[110]. - The company has maintained a continuous relationship with the auditing firm for 9 years, with an audit fee of 320,000 yuan for the year[109]. - The company has not faced any penalties or rectification issues during the reporting period[111].
贝瑞基因(000710) - 2014 Q3 - 季度财报
2014-10-27 16:00
Financial Performance - Operating revenue for the reporting period was CNY 54,519,664.98, up 10.99% year-on-year[7] - Net profit attributable to shareholders was a loss of CNY 2,524,048.20, a decrease of 36.28% compared to the same period last year[7] - Basic earnings per share were CNY -0.0167, a decrease of 36.26% year-on-year[7] - The weighted average return on equity was -2.20%, a decrease of 1.29% compared to the previous year[7] - The company reported a total of CNY -5,031,487.56 in non-recurring gains and losses for the year-to-date[8] - Non-operating income increased by 57.01% year-on-year, mainly due to gains from the disposal of non-current assets[15] Asset and Investment Changes - Total assets increased by 15.46% to CNY 473,502,876.47 compared to the end of the previous year[7] - Accounts receivable increased by 89.97% compared to the beginning of the year, mainly due to an increase in bank acceptance bills received from customers[15] - Long-term equity investments increased by 57.83% compared to the beginning of the year, primarily due to investment income from Tianxing Shantian[15] - Prepayments increased by 68.65% compared to the beginning of the year, mainly due to an increase in advance sales payments[15] - Investment income increased by 1724.52% year-on-year, primarily driven by investment income from Tianxing Shantian[15] Expenses and Liabilities - Financial expenses increased by 65.73% year-on-year, mainly due to increased interest expenses[15] - Special payables increased by 2742.01% compared to the beginning of the year, primarily due to relocation compensation for the new factory[15] - Management expenses increased by 31.90% year-on-year, mainly due to increased restructuring costs[15] - Other receivables increased by 51.31% compared to the beginning of the year, mainly due to an increase in inter-company transactions[15] - Other payables increased by 32.24% compared to the beginning of the year, mainly due to an increase in inter-company transactions[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,059[10] - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., held 58.86% of the shares, totaling 89,002,000 shares[11] Business Operations and Strategy - Chengdu Tianxing Instrument Co., Ltd. reported that its main business involves the design, production, processing, and sales of motorcycle and automotive parts[20] - The company is actively advancing its major asset restructuring work, with a focus on avoiding competition with its controlling shareholder[20] - The new factory construction is currently in progress, with a construction period estimated at 2-3 years[21] - The company has completed land leveling, drilling, and design for the new site[21] - The company has signed a land use rights transfer contract for 60,675.53 square meters[20] Compliance and Governance - The company has committed to minimizing related party transactions and ensuring fair pricing in any unavoidable transactions[21] - The company guarantees that it will not engage in any business activities that may compete with Tianxing Instrument and its subsidiaries[21] - The company has pledged to comply with legal and regulatory requirements regarding related party transactions and information disclosure[21] - The company aims to ensure that no unfair advantages are given to existing shareholders in market transactions[21] Challenges and Future Outlook - The company is facing significant operational difficulties and requires external assistance to restructure its business model to enhance core competitiveness[22] - The planned major asset restructuring involving the acquisition of 100% equity of Xigang Group Lighthouse Mining Co., Ltd. has been suspended due to unmet preconditions[22] - The company has committed to clarifying property rights and ensuring that daily related transactions with the controlling shareholder do not harm the company's interests[22] - There is a warning that the cumulative net profit from the beginning of the year to the next reporting period may experience significant fluctuations compared to the same period last year[24] Investment Activities - The company did not engage in any securities or derivative investments during the reporting period[25] - The company has not held any equity in other listed companies during the reporting period[24] Communication with Investors - Communication with individual investors regarding production operations and major asset restructuring has occurred, but no materials were provided[26]
贝瑞基因(000710) - 2014 Q2 - 季度财报
2014-08-29 16:00
Financial Performance - The company's operating revenue for the first half of 2014 was CNY 157,054,977.84, representing a 5.91% increase compared to CNY 148,292,347.35 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was a loss of CNY 4,605,072.47, a decrease of 71.20% from a loss of CNY 2,689,918.87 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 416,052.78, an increase of 115.41% compared to a loss of CNY 2,699,197.31 in the same period last year[20]. - The operating profit for the first half of 2014 was a loss of CNY 4,738,100, a decrease of 75.27% compared to the previous year[28]. - The company reported a net loss of ¥91,827,417.03, worsening from a loss of ¥87,222,344.56 in the previous period[110]. - The net profit for the current period is -¥4.48 million, worsening from -¥2.57 million in the previous period, reflecting ongoing financial challenges[119]. Cash Flow and Liquidity - The net cash flow from operating activities was a negative CNY 20,067,634.72, which is a decline of 41.84% from a negative CNY 14,148,502.33 in the previous year[20]. - The cash flow from operating activities was negative at -¥20,067,634.72, worsening by 41.84% compared to -¥14,148,502.33 in the previous year[30]. - The net cash flow from operating activities is -¥20.07 million, a decline from -¥14.15 million in the previous period, indicating increased cash outflows[122]. - The net cash flow from investment activities was 1,200,715.08 CNY, a significant improvement from -45,974,833.29 CNY in the previous period[126]. - The ending balance of cash and cash equivalents was 17,231,510.12 CNY, down from 12,975,086.49 CNY in the previous period[127]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 422,802,306.59, reflecting a 3.10% increase from CNY 410,084,460.18 at the end of the previous year[20]. - Total liabilities rose to ¥306,478,921.39, up from ¥289,086,709.44, indicating a 6.5% increase[110]. - The company's equity attributable to shareholders decreased to ¥110,834,010.80 from ¥115,439,083.27, a decline of 4.2%[110]. - The total owner's equity at the end of the current period is CNY 112,295,470, down from CNY 116,772,850 at the beginning of the year[135]. Market and Operational Strategy - The company is focused on expanding new markets and improving internal management despite facing macroeconomic pressures and increased competition[28]. - The company did not disclose any future development plans or strategies in its public documents[31]. - The company has made commitments regarding the restructuring of Tianxing Instrument to enhance its core competitiveness amid operational difficulties[84]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 13,657[94]. - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., holds 58.86% of the shares, totaling 89,002,000 shares, with 32,310,000 shares pledged[95]. - There were no changes in the controlling shareholder or actual controller during the reporting period[97]. Related Party Transactions - The company engaged in related party transactions amounting to 6,882.92 million yuan, with various transactions including sales and purchases at market prices[64][65]. - The related party transactions did not have a significant impact on the company's operating results and financial status[69]. Compliance and Governance - There were no significant litigation or arbitration matters during the reporting period[56]. - The company confirmed the normal performance of commitments made by controlling shareholders regarding independence and avoidance of competition[81][82]. - There are no penalties or rectification measures reported during the reporting period, indicating compliance with regulations[86]. Accounting Policies - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that the financial statements accurately reflect its financial position as of June 30, 2014[142]. - The company uses RMB as its functional currency for accounting purposes[144]. - The company recognizes revenue from the sale of goods when the main risks and rewards of ownership are transferred to the buyer, and the economic benefits related to the sale can be reliably measured[187].
贝瑞基因(000710) - 2014 Q1 - 季度财报
2014-04-27 16:00
Financial Performance - The company's operating revenue for Q1 2014 was ¥53,871,913.31, a decrease of 21.25% compared to ¥68,406,407.56 in the same period last year[8] - The net profit attributable to shareholders was a loss of ¥1,499,277.09, showing a slight improvement of 3.3% from a loss of ¥1,550,374.78 in the previous year[8] - The net cash flow from operating activities was negative at ¥24,638,589.25, a significant decline of 715.69% compared to a positive cash flow of ¥4,001,753.38 in the same period last year[8] - Total assets at the end of the reporting period were ¥389,877,086.10, down 4.93% from ¥410,084,460.18 at the end of the previous year[8] - The weighted average return on net assets was -1.31%, slightly improved from -1.32% in the previous year[8] - Tax and additional fees decreased by 68.67% year-on-year, mainly due to reduced product gross margins[15] - Financial expenses increased by 53.9% year-on-year, primarily due to higher interest expenses[15] - Investment income increased by 100% year-on-year, mainly from investments in Chengdu Tianxing Shantian Automotive Parts Co., Ltd.[15] Shareholder Information - The number of shareholders at the end of the reporting period was 13,881, with the largest shareholder holding 58.86% of the shares[11] Operational Independence - The company is committed to ensuring the independence of its personnel, assets, business, and finances, with ongoing compliance with the commitments made during the acquisition process[18] - The company has established an independent financial department and accounting system, ensuring that it operates independently from its controlling shareholders[19] - The company guarantees that its financial personnel do not hold positions in the controlling shareholder's subsidiaries, ensuring financial independence[19] - The company has committed to maintaining an independent operational capability, with a focus on market-driven sustainable operations[19] - The company has not invested in any businesses that compete with its main operations in motorcycle and automotive parts design, production, and sales[19] - The company has a commitment to avoid any business activities that may compete with its subsidiaries, ensuring no conflict of interest[19] - The company has made a long-term commitment to maintain the independence of its board and management decisions[18] Market Expansion and Restructuring - The company is actively working on the restructuring of its assets, including resolving issues related to property and land rights[19] - The company is in the process of expanding its market presence and is actively pursuing business opportunities that align with its core operations[19] - The company is currently engaged in ongoing discussions regarding potential acquisitions to enhance its market position[19] - Chengdu Tianxing Instrument Co., Ltd. reported that the main business involves the design, production, processing, and sales of motorcycle and automotive parts[20] - The company has completed land leveling, drilling, and design for a new factory area, with a construction period of 2-3 years[20] - Tianxing Instrument is facing significant operational difficulties and plans to adjust its business structure to enhance core competitiveness[22] - The company has committed to resolving the separation of property and land rights within 12 months after the completion of the current acquisition[22] Investment Activities - The company has not made any securities investments during the reporting period, with no shares held[25] - No derivative investments were reported during the period, with a total initial investment of 0 and a year-end investment amount also at 0, representing 0% of the company's net assets[26] - The company did not disclose any information regarding the approval dates for derivative investments by the board or shareholders[26] Profit Warning - There is a warning regarding the potential for significant changes in net profit for the first half of 2014 compared to the previous year[25]
贝瑞基因(000710) - 2013 Q4 - 年度财报
2014-04-18 16:00
Financial Performance - The company's operating revenue for 2013 was ¥262,234,824.69, a decrease of 20.79% compared to ¥331,077,628.33 in 2012[22]. - The net profit attributable to shareholders was -¥6,156,854.77, representing a significant decline of 1,666.69% from a profit of ¥392,984.52 in the previous year[22]. - The net cash flow from operating activities decreased by 67.62% to ¥15,627,955.37, down from ¥48,265,432.09 in 2012[22]. - The basic earnings per share were -¥0.0407, a drop of 1,665.38% compared to ¥0.0026 in 2012[22]. - The weighted average return on net assets was -5.36%, a decline from 0.34% in the previous year[22]. - The net profit attributable to the parent company was CNY -615.69 million, a decline of 1,666.69% year-on-year[32]. - The company reported a net loss of RMB 87,222,344.56 for the year, compared to a loss of RMB 81,065,489.79 in the previous year, indicating a worsening of approximately 7.3%[191]. - The net loss for the period was CNY 6,229,471.78, compared to a net profit of CNY 221,802.64 in the previous period, indicating a significant decline in profitability[197]. Assets and Liabilities - Total assets increased by 20.25% to ¥410,084,460.18 at the end of 2013, up from ¥341,017,987.60 at the end of 2012[22]. - The total assets of Chengdu Tianxing Instrument Co., Ltd. as of December 31, 2013, amounted to RMB 410,084,460.18, an increase from RMB 341,017,987.60 at the beginning of the year, representing a growth of approximately 20.3%[190]. - The company's total liabilities increased to RMB 289,086,709.44 from RMB 217,337,616.16, reflecting a rise of about 32.9%[191]. - Total liabilities rose to CNY 288,287,258.44, up from CNY 217,288,165.16, marking an increase of 32.8%[195]. - The total owner's equity decreased to RMB 120,997,750.74 from RMB 123,680,371.44, indicating a decline of approximately 2.2%[191]. - Owner's equity decreased to CNY 116,772,859.18 from CNY 120,179,898.18, a decline of 2.9%[195]. Cash Flow - The cash flow from operating activities decreased by 67.62% year-on-year, primarily due to increased cash payments related to operating activities[44]. - The company's cash and cash equivalents decreased by CNY 18,826,800.62, a decline of 170.77% compared to the previous year[44]. - The company's cash and cash equivalents net increase decreased by 170.77% year-on-year, mainly due to increased cash payments for Tianxing Shantian equity and increased cash from bank loans[45]. - Cash and cash equivalents at the end of 2013 were RMB 101,214,424.58, up from RMB 86,665,225.20, marking an increase of about 16.5%[189]. Investment Activities - Investment cash inflow increased by 345.04% year-on-year, mainly due to an increase in cash received related to other investment activities[45]. - Investment cash outflow increased by 182.51% year-on-year, primarily due to increased cash payments for Tianxing Shantian equity[45]. - Net cash flow from investment activities decreased by 180.67% year-on-year, mainly due to increased cash payments for Tianxing Shantian equity[45]. - Net cash flow from financing activities increased by 484.61% year-on-year, primarily due to increased cash received from bank loans[45]. Business Operations - The company has detailed risk factors that may affect its future development in the report[13]. - The decline in performance is attributed to rising raw material and labor costs, alongside a decrease in production scale and product sales prices[81]. - The company has not made any changes to its main business since its listing[19]. - The company’s main business revenue accounted for 95.19% of total operating revenue, amounting to CNY 249,627,776.26[33]. - The company’s total operating costs were CNY 229,426,208.40, with main business costs at CNY 217,410,235.74, accounting for 94.87% of total costs[39]. - The company’s financial expenses increased by 97.55% compared to the previous year, mainly due to higher interest expenses[42]. - The company’s gross profit margin for automotive parts was 82.8%, up from 66.91% in the previous year, indicating a 15.89% increase[39]. Research and Development - The company’s R&D expenditure was CNY 12.73 million, representing 10.52% of net assets and 4.85% of operating revenue[43]. - The company developed 107 new products during the reporting period, including 61 automotive instruments, 31 motorcycle instruments, and 13 sensors[59]. Shareholder Information - The total number of shares is 151,200,000, with 100% being unrestricted shares[135]. - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., holds 58.86% of the shares, totaling 89,002,000 shares[140]. - The total number of shareholders at the end of the reporting period is 13,681[140]. - The company has not distributed cash dividends in the past three years due to negative retained earnings, with the latest net profit for 2013 reported at -6,156,854.77 yuan[91][89]. Corporate Governance - The company’s governance structure complies with the requirements of the Company Law and relevant regulations from the China Securities Regulatory Commission[165]. - The company has established a management system for insider information to prevent misuse of sensitive information[166]. - The company maintains independence from its controlling shareholder in business, personnel, assets, organization, and finance, ensuring a complete and independent operational structure[175]. - The company has established a performance evaluation and incentive system for senior management, with monthly checks and annual assessments conducted[177]. - No significant deficiencies in internal control over financial reporting were identified during the reporting period[181]. Future Outlook - The company aims for a certain percentage increase in revenue, total profit, and net profit for the fiscal year 2014[83]. - The focus will be on expanding automotive instrument products, particularly targeting B and C class vehicles, while stabilizing the micro vehicle market and developing electronic motorcycle instruments[83]. - The company plans to enhance quality management and control processes to reduce market return losses and improve user satisfaction[83]. - There is a commitment to strengthen independent innovation and technical breakthroughs, with an emphasis on optimizing the development organization and increasing talent acquisition[83]. - The company is currently facing operational difficulties and is seeking external assistance to restructure its business model and enhance core competitiveness[126].